A phase 3 study of Gossamer Bio’s seralutinib in pulmonary arterial hypertension (PAH) has missed its primary endpoint, triggering a 77% crash in the biotech’s share price. The company has paused ...
Gossamer Bio, Inc. engages in discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. Its primary product candidate, GB001, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results